Figure 2From: Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy PAI-1 expression and cancer-specific survival in 162 patients with CCRCC undergoing radical nephrectomy.Back to article page